Chemours™

The Chemours Company

Third Quarter Earnings Presentation

November 3, 2017

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words "believe," "expect," “will,” "anticipate," "plan," "estimate," “anticipate,” "target," "project" and similar expressions, among others, generally identify "forward-looking statements" which speak only as of the date the statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, litigation and other legal proceedings or contingencies, anticipated future operating and financial performance, business plans and prospects, transformation plans, cost savings targets, plans to increase profitability and our outlook for Adjusted EBITDA and Free Cash Flow, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties which are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2016. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, which should not be considered as replacements of GAAP. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin and Free Cash Flow to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company’s website at investors.chemours.com.

Third Quarter 2017 Highlights

Strong year-over-year performance with improvement across all key financial metrics

Strengthened demand for Ti-Pure™ TiO_2 paired with favorable pricing actions

Increased Opteon™ refrigerant sales and solid demand for fluoropolymers products

Reaffirmed full-year 2017 Adjusted EBITDA outlook; now expect positive Free Cash Flow

Chemours™

3Q17 Overview

($ in millions, except per share statistics, unless otherwise noted)

Third Quarter Financial Summary

	3Q17	3Q16	Δ Yr/Yr
Net Sales	$1,584	$1,398	$186
Net Income[1]	207	204	3
Adj. Net Income	214	112	102
EPS[2]	$1.08	$1.11	($0.03)
Adj. EPS[2]	$1.12	$0.61	$0.51
Adj. EBITDA	381	268	113
Adj. EBITDA Margin (%) [3]	24	19	5
Free Cash Flow[4]	324	131	193
Pre-Tax ROIC(%)[5]	32	12	20

Year-Over-Year

- Results primarily driven by increased sales of Ti-Pure™ titanium dioxide
- Adjusted EBITDA margin improvement of ~500 basis points, primarily from higher prices and volumes
- Free Cash Flow of $324M, excluding $320M PFOA payment
- Strong expansion in Pre-Tax ROIC

[1] Net Income attributable to Chemours. 3Q16 net income included a gain of $169 million from the sale of a business in Chemical Solutions
[2] Calculation based on diluted share count
[3] Defined as Adjusted EBITDA divided by Net Sales
[4] Defined as Cash from Operations minus cash used for PP&E purchases, not including $320M PFOA payment
[5] Defined as Adjusted EBITDA on a trailing twelve-month basis less depreciation & amortization divided by average invested capital over the last five quarters
See reconciliation of non-GAAP measures in the Appendix

Chemours™

Adjusted EBITDA Bridge: 3Q17 versus 3Q16

($ in millions)



See reconciliation of Non-GAAP measures in the Appendix

Liquidity Position

($ in millions)



- Free Cash Flow of $324M[1] versus $131M in 3Q16
- Cash position unchanged after completing our portion of PFOA settlement payment during the quarter
- Working capital release of $140M, excluding PFOA payment
- Total Liquidity of ~$2.2B, including revolver availability of $750M[2]
- Net debt of $2.6B, net leverage ratio[3] of ~2.0 times on a trailing twelve month basis

[1] Includes cash restructuring payments of $12 million in 3Q17, excludes $320M of PFOA payment
[2] Chemours had $102M in Letters of credit outstanding as of September 30, 2017
[3] Senior Secured Net Debt/EBITDA is 0.74x based on Credit Agreement definition
* Net Income attributable to Chemours

Chemours™

Titanium Technologies Business Summary

Third Quarter Highlights

- Communicated price increases through customer letters during the quarter; price increases vary by application, grade and end-user
- Volume increases driven by customer desire for reliable, high-quality supply of Ti-Pure™ titanium dioxide
- Manufacturing facilities utilized at full capacity

Outlook Commentary

- Full-year volume anticipated to increase by high single-digits percentage year-over-year
- Manufacturing facilities projected to maintain operations at full utilization to meet customer demand
- Fourth quarter average realized price expected to reflect previously communicated price increases

Financial Summary *($ millions)*

	3Q17	3Q16	Δ Yr/Yr
Sales	$799	$625	$174
Adjusted EBITDA	$249	$144	$105
Adjusted EBITDA Margin (%)	*31*	*23*	*8*

Sales Drivers

	Yr/Yr % Δ
Price[1]	18
Currency	2
Volume	8

[1] TiO_2 global average price was up 18%, excluding other minor product revenue

Chemours™

See Segment Net Sales and Adjusted EBITDA measures in the Appendix

Fluoroproducts Business Summary

Third Quarter Highlights

- Opteon™ refrigerant revenue up approximately 50% compared to very strong third quarter in the previous year driven by EU MAC directive
- Base refrigerant lower volume in line with seasonal expectations
- Fluoropolymers benefitted from volume increases; reached an inflection point in fluoropolymers pricing

Outlook Commentary

- Nearing one year anniversary of EU MAC directive; US adoption pace on target
- HFO-based blends adoption for European stationary applications ramping up according to plan, driven by F-gas directive
- Opteon™ Corpus Christi expansion progressing as planned; construction expected to be complete in late 2018
- Favorable demand for fluoropolymers across product lines expected to continue

Financial Summary *($ millions)*

	3Q17	3Q16	Δ Yr/Yr
Sales	$637	$591	$46
Adjusted EBITDA	$158	$143	$15
Adjusted EBITDA Margin (%)	*25*	*24*	*1*

Sales Drivers

	Yr/Yr % Δ
Price	2
Currency	1
Volume	5

Chemours™

See Segment Net Sales and Adjusted EBITDA measures in the Appendix

Chemical Solutions Business Summary

Third Quarter Highlights

- Volume increase due to higher demand for Mining Solutions and Performance Chemicals & Intermediates products
- Higher average price in Performance Chemicals & Intermediates offset by lower average price in Mining Solutions
- Continued impact on sales and Adjusted EBITDA from 2016 divestitures and site closure

Outlook Commentary

- Demand for Mining Solutions anticipated to remain strong
- Mining Solutions annual planned maintenance outage in 4Q
- Performance Chemicals & Intermediates product lines expected to improve to breakeven performance
- New Mining Solutions manufacturing facility on track; expected to complete construction in late 2018

Financial Summary *($ millions)*

	3Q17	3Q16	Δ Yr/Yr
Sales	$148	$182	($34)
Adjusted EBITDA	$18	$9	$9
Adjusted EBITDA Margin (%)	*12*	*5*	*7*

Sales Drivers

	Yr/Yr % Δ
Price	0
Currency	0
Volume	5
Portfolio	(24)

Chemours™

See Segment Net Sales and Adjusted EBITDA measures in the Appendix

2017 Outlook Reaffirmed

2017 Adjusted EBITDA Expected To Be Between $1.3 - $1.4 Billion With Positive Free Cash Flow[1]

Key Factors Influencing Market Performance

Market Factors

- TiO_2 price
- Currency
- End-market demand
- Seasonality
- Regulatory uncertainty

Chemours Initiatives

- Cost reductions
- Altamira expansion ramp-up
- Opteon™ market adoption
- Corpus Christi expansion
- Impacts from divestitures

[1]Including Payment of PFOA MDL Settlement

Chemours™

See reconciliation of estimated Adjusted EBITDA in Appendix

Appendix

GAAP Net Income to Adjusted Net Income and Adjusted EBITDA Reconciliations

GAAP Net Income to Adjusted Net Income and Adjusted EBITDA Tabular Reconciliations

($ in millions except per share amounts)	Three months ended September 30, 2017		Three months ended September 30, 2016		Three months ended June 30, 2017	
	$ amounts	$ per share	$ amounts	$ per share	$ amounts	$ per share
Net income attributable to Chemours	$ 207	$ 1.12	$ 204	$ (0.10)	$ 161	$ 0.87
Non-operating pension and other post-retirement employee benefit income	(7)	(0.04)	(5)	(0.04)	(10)	(0.05)
Exchange losses (gains)	4	0.02	17	0.08	(2)	(0.01)
Restructuring charges	8	0.04	14	0.05	6	0.03
Asset-related charges	1	0.01	46	0.35	2	0.01
(Gain) loss on sale of assets or businesses	-	-	(169)	0.01	2	0.01
Transaction costs	1	0.01	2	0.07	2	0.01
Legal and other charges	7	0.04	5	0.07	10	0.05
(Benefit from) provision for income taxes relating to reconciling items [1]	(7)	(0.04)	(2)	(0.21)	(5)	(0.03)
Adjusted Net Income [3]	$ 214	$ 1.15	$ 112	$ 0.27	$ 166	$ 0.90
Net income attributable to non-controlling interests	-		-		-	
Interest expense, net	55		51		55	
Depreciation and amortization	62		73		71	
All remaining provision for income taxes [1]	50		32		69	
Adjusted EBITDA	$ 381		$ 268		$ 361	
Weighted average number of common shares outstanding - basic	185,431,036		181,596,161		185,069,436	
Weighted average number of common shares outstanding - diluted	191,637,814		183,528,556		191,126,639	
Earnings per share - basic	$ 1.12		$ 1.12		$ 0.87	
Earnings per share - diluted [2]	$ 1.08		$ 1.11		$ 0.84	
Adjusted earnings per share - basic	$ 1.15		$ 0.62		$ 0.90	
Adjusted earnings per share - diluted [2]	$ 1.12		$ 0.61		$ 0.87	

[1] Total of provision for (benefit from) income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three months ended September 30, 2017 and 2016, and for the three months ended June 30, 2017.

[2] Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

[3] Immaterial differences may exist in summation of per share amounts due to rounding.

Chemours™

Free Cash Flow Reconciliation

GAAP Cash Flow to Free Cash Flow Tabular Reconciliations

($ in millions unless otherwise noted)	Three months ended			Nine months ended	
	September 30,		June 30,	September 30,	
	2017	2016	2017	2017	2016
Cash flow provided by operating activities [1 2]	$ 112	$ 198	$ 183	$ 336	$ 324
Cash flow used for purchases of property, plant and equipment	(108)	(67)	(69)	(246)	(235)
Free Cash Flow	$ 4	$ 131	$ 114	$ 90	$ 89

[1] Cash flow provided by operating activities for the nine months ended September 30, 2017 and 2016 include the DuPont prepayment of $190 million received in the first quarter of 2016, of which $0 million and $93 million remain outstanding as of September 30, 2017 and 2016, respectively. Excluding the DuPont prepayment, Free Cash Flow for the nine months ended September 30, 2016 would have been negative $4 million.

[2] Cash flow provided by operating activities for the three and nine months ended September 30, 2017 include PFOA MDL settlement payments of $320 million and $335 million, respectively. Excluding the PFOA MDL settlement payments, Free Cash Flow for the three and nine months ended September 30, 2017 would have been $324 million and $425 million, respectively.

Chemours™

Segment Net Sales and Adjusted EBITDA (unaudited)

SEGMENT NET SALES AND ADJUSTED EBITDA (UNAUDITED)

($ in millions unless otherwise noted)

	Three months ended September 30, 2017	Three months ended September 30, 2016	Three months ended June 30, 2017
SEGMENT NET SALES			
Titanium Technologies	$ 799	$ 625	$ 729
Fluoroproducts	637	591	710
Chemical Solutions	148	182	149
Total Company	$ 1,584	$ 1,398	$ 1,588
SEGMENT ADJUSTED EBITDA			
Titanium Technologies	$ 249	$ 144	$ 193
Fluoroproducts	158	143	197
Chemical Solutions	18	9	7
Corporate & Other	(44)	(28)	(36)
Total Company	$ 381	$ 268	$ 361
SEGMENT ADJUSTED EBITDA MARGIN			
Titanium Technologies	31.2%	23.0%	26.5%
Fluoroproducts	24.8%	24.2%	27.7%
Chemical Solutions	12.2%	4.9%	4.7%
Corporate & Other	0.0%	0.0%	0.0%
Total Company	24.1%	19.2%	22.7%

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Reconciliation of Outlook

2017 Estimated GAAP Net Income to Estimated Adjusted EBITDA Tabular Reconciliation

(UNAUDITED)

($ in millions unless otherwise noted)

Estimated Net Income [1]	$605 - 680
Provision for income taxes [1 2]	195 - 220
Interest expense, net	~ 220
Depreciation and amortization	~ 280
Other reconciling items [1 3]	~ (0)
Estimated Adjusted EBITDA [1]	$1,300 - 1,400

[1] *Our estimates reflect our current visibility and expectations of market factors, such as but not limited to, currency movements, TiO2 prices and end-market demand. Actual results could differ materially from the current estimates due to market factors and unknown or uncertainty of other factors, such as an estimate of non-operating pension benefit costs with respect to our foreign pension plans including settlements or curtailments, cost savings actions that may be taken in the future, the impact of currency movements on our results including exchange gains and losses and the related tax effects.*

[2] *Provisions for income tax is based on our current estimate of geographic mix of earnings and does not include potential tax effect of future discrete items.*

[3] *Includes non-operating pension benefit income, exchange gains and losses, gain on sale of assets, restructuring and other charges recognized in the first half of 2017.*

Chemours™